It can be difficult to keep up with the current research programs and clinical trials accepting new patients. This page is all about the current clinical trials for women with alloimmunization and children with HDFN. If you have a research program or trial that you would like added to this list, please contact us.
"Participants must have an obstetrical history of severe fetal anemia, hydrops, or stillbirth related to hemolytic disease of the fetus and newborn, have alloantibody titers for anti-D ≥32 or anti-Kell titers ≥4, and be currently pregnant with an antigen-positive fetus. Eligible women may enter the study at any time during the current pregnancy prior to delivery. Pregnant female participants must be ≥18 years of age with an estimated Gestational Age of ≥ 8 weeks; not currently pregnant with multiples (twins or more); and no other clinically relevant abnormalities currently or in their history that the Investigator would deem them ineligible to participate."
"Pregnant female participants must be ≥18 years of age with an estimated gestational age of 8 to 13 weeks at enrollment; a previous pregnancy with a gestation that included at least one condition [severe fetal anemia, fetal hydrops (ascites), or stillbirth with fetal or placental pathology indicative of Hemolytic Disease of the Fetus and Newborn] at ≤24 weeks gestation; not currently pregnant with multiples (twins or more), up to date on required immunizations; and no other clinically relevant abnormalities currently or in their history that the Investigator would deem them ineligible to participate."
"All (near)-term neonates (gestational age ≥ 35 weeks) admitted to the Leiden University Medical Center (LUMC) with HDFN, treated with IUT."
"Blood samples of pregnant couples, gender/nation/region is unlimited."
"Up to 14 days old. Healthy term and late-preterm neonates more than or equal to 35 weeks gestation with hemolytic disease of the newborn will be included. Enrolled infants should have evidence of hemolysis as defined by any of the following criteria: (1) positive DAT and blood group iso-immunization (ABO / RH incompatibility);and /or (2) HGB decline by 2g/dl within 24hours."